GeneDx Holdings Corp (WGS)

Currency in USD
105.85
-0.80(-0.75%)
Closed·
After Hours
103.56-2.29(-2.16%)
·
WGS Scorecard
Full Analysis
Net income is expected to grow this year
WGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
102.36106.82
52 wk Range
28.86117.75
Key Statistics
Prev. Close
106.65
Open
106.82
Day's Range
102.36-106.82
52 wk Range
28.86-117.75
Volume
736.96K
Average Volume (3m)
1M
1-Year Change
267.28%
Book Value / Share
9.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WGS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
115.29
Upside
+8.91%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

GeneDx Holdings Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy

GeneDx Holdings Corp Company Profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.

GeneDx Holdings Corp Earnings Call Summary for Q2/2025

  • GeneDx Q2 2025 EPS of $0.50 beat $0.12 forecast; revenue of $102.7M exceeded $85.45M estimate; stock surged 24.36% pre-market
  • 49% YoY revenue growth; record 71% adjusted gross margin; exome and genome revenues up 69% YoY; fourth consecutive profitable quarter
  • Full-year revenue guidance set at $400M-$415M; exome and genome revenue expected between $345M-$355M; 30%+ volume growth anticipated
  • CEO highlights leadership in rare disease diagnosis; focus on early genetic information delivery and proactive healthcare approach
  • Expansion plans include pediatric market growth by 2026; NICU testing implementation; potential challenges with Medicaid billing noted
Last Updated: 29/07/2025, 15:30
Read Full Transcript

Compare WGS to Peers and Sector

Metrics to compare
WGS
Peers
Sector
Relationship
P/E Ratio
2,162.6x−1.1x−0.5x
PEG Ratio
21.56−0.010.00
Price/Book
11.0x0.9x2.6x
Price / LTM Sales
8.4x1.2x3.3x
Upside (Analyst Target)
10.6%51.7%43.5%
Fair Value Upside
Unlock17.3%6.9%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 115.29
(+8.91% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
0.50 / 0.12
Revenue / Forecast
102.70M / 85.45M
EPS Revisions
Last 90 days

WGS Income Statement

People Also Watch

174.39
ALAB
+28.66%
161.71
CRCL
+5.05%
45.930
SMR
+1.77%
51.790
ASTS
-1.48%
83.10
OKLO
-1.18%

FAQ

What Stock Exchange Does GeneDx Holdings Trade On?

GeneDx Holdings is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for GeneDx Holdings?

The stock symbol for GeneDx Holdings is "WGS."

What Is the GeneDx Holdings Market Cap?

As of today, GeneDx Holdings market cap is 3.04B.

What Is GeneDx Holdings's Earnings Per Share (TTM)?

The GeneDx Holdings EPS (TTM) is 0.05.

When Is the Next GeneDx Holdings Earnings Date?

GeneDx Holdings will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is WGS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has GeneDx Holdings Stock Split?

GeneDx Holdings has split 1 times.

How Many Employees Does GeneDx Holdings Have?

GeneDx Holdings has 1000 employees.

What is the current trading status of GeneDx Holdings (WGS)?

As of 07 Aug 2025, GeneDx Holdings (WGS) is trading at a price of 105.85, with a previous close of 106.65. The stock has fluctuated within a day range of 102.36 to 106.82, while its 52-week range spans from 28.86 to 117.75.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.